Pfizer Inc. (PFE) AI Stock Analysis

Pfizer Inc. operates as a leading global biopharmaceutical company, specializing in the discovery, development, manufacturing, marketing, distribution, and sale of medicines and vaccines. Its portfolio spans cardiovascular metabolic health, women's health, oncology, immunology, and infectious diseases, featuring brands such as Eliquis, Ibrance, and the COVID-19 vaccine Comirnaty. Pfizer also provides sterile injectables, anti-infectives, oral COVID-19 treatments, and biosimilar therapies like Xeljanz and Enbrel. In addition to biopharmaceuticals, the company provides contract manufacturing services to wholesalers, retailers, hospitals, clinics, and government agencies globally, collaborating with partners such as Bristol-Myers Squibb, BioNTech, and Merck KGaA.

Pfizer's revenue shifted from $81.29B in FY2021 to a peak of $100.33B in FY2022 before dropping to $59.55B in FY2023. Annual revenue rebounded to $63.63B in FY2024 before decreasing 1.6% to $62.58B in FY2025. Gross margin expanded over this period, reaching 70.3% in FY2025 alongside an operating margin of 24.7% and net income of $7.77B. Diluted earnings per share were $3.23 in FY2025, compared to $3.11 in FY2024. Over the trailing twelve months, revenue reached $63.70B with net margin of 6.8%. In the latest quarter ending June 30, 2026, revenue increased 2.6% year-over-year, while quarterly earnings declined 10.1%.

As of June 30, 2026, Pfizer held $11.70B in cash and short-term investments against $63.19B in total debt, resulting in net debt of $51.49B. Total assets stood at $201.13B and shareholders' equity was $85.19B. The company maintained a current ratio of 1.27 and a debt-to-equity ratio of 0.74. In FY2025, operating cash flow reached $11.71B and free cash flow was $9.08B. Cash deployment in FY2025 included $2.63B in capital expenditures and $9.77B in dividends paid, while share count changed -1.2% over 5 years.

At a last close of $29.58, Pfizer trades at a trailing price-to-earnings ratio of 38.9x, above the 27.2x median of its S&P 500 Healthcare peers. However, its forward P/E ratio of 9.7x is lower than the peer median of 16.6x. The company's price-to-sales ratio is 2.6x versus the peer median of 3.4x, and its EV-to-EBITDA ratio is 15.7x compared to the peer median of 15.0x. Over the past year, Pfizer delivered a return of 30.6%, outperforming the S&P 500 SPY return of 16.8%, but its 5-year return of -7.1% trails the S&P 500 SPY return of 83.0%.

Pfizer pays an annualized forward dividend of $1.72 per share, yielding 5.81% as of October 16, 2026. Dividends are distributed on a quarterly frequency, with the payout ratio at 56.4%. Pfizer has paid dividends for 55 consecutive years and generated a 5-year annualized dividend growth rate of 3.6%. The company paid $9.77B in total dividends during FY2025, and its last ex-dividend date was November 6, 2026.

Wall Street coverage includes 8 Strong Buy, 2 Buy, 16 Hold, 1 Sell, and 1 Strong Sell ratings. The mean price target is $29.26, which sits 1.1% below the last close of $29.58. For the fiscal year ending December 31, 2026, analysts estimate EPS of $2.96 on revenue of $62.22B. For the following fiscal year, 23 analysts project EPS of $2.89 on revenue of $59.86B. Pfizer beat EPS estimates in all 4 of its last 4 quarters, with its next earnings report scheduled for November 3, 2026.

This page is an AI-written research summary of Pfizer Inc. (PFE). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: PFE income statement, PFE balance sheet, PFE key metrics, PFE analyst forecast, PFE chart. See the PFE stock overview for the latest quote and news.